Fusion Proteins Comprising an Improved GLP-1 Receptor Agonist and Uses Thereof

Abstract

This invention relates to an improved GLP-1 receptor agonist, a fusion protein comprising the improved GLP-1 receptor agonist, a nucleic acid encoding the fusion protein, a vector and cell comprising the nucleic acid, and uses thereof. Specifically, the present invention provides a modified and improved GLP-1-IgG2/Fc fusion protein, a nucleic acid encoding the fusion protein, a vector and cell comprising the nucleic acid, and a composition thereof. The invention further relates to use of the fusion protein, nucleic acid, vector, cell and composition thereof in the manufacture of a medicament for the treatment or prevention of metabolic diseases associated with glucose or lipid metabolism disorders, as well as neurological disorders and other diseases.

Figure 8